| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
2,7-Dibromocarbazole exhibits notable antibacterial activity, particularly against methicillin-resistant Staphylococcus aureus (MRSA) strains. It enhances the effectiveness of oxacillin by significantly lowering its minimum inhibitory concentration (MIC). The compound does not have a defined pharmacological target for therapeutic applications but shows potential as an antibacterial agent.
|
|---|---|
| ln Vitro |
In vitro, 2,7-dibromocarbazole exhibits notable antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) strains. It enhances the effectiveness of oxacillin by significantly lowering its minimum inhibitory concentration (MIC). The compound is used as a biochemical reagent and building block for the synthesis of various compounds that are subsequently tested in in vitro assays. It is also used in materials science for OLED and OPV development.
|
| ln Vivo |
In vivo data for 2,7-dibromocarbazole as a therapeutic agent are not available, as the compound is primarily used as a building block for materials science and chemical synthesis. Its antibacterial activity has been demonstrated in vitro, but specific in vivo efficacy and pharmacokinetic data are not documented. The compound's in vivo relevance is indirect, through the biological activities of the final compounds derived from it.
|
| Enzyme Assay |
For in vitro antibacterial assays, 2,7-dibromocarbazole is evaluated against bacterial strains such as methicillin-resistant Staphylococcus aureus (MRSA). Standard broth microdilution methods are used to determine the minimum inhibitory concentration (MIC). The compound is tested at various concentrations (typically 0.1-100 µg/mL) and incubated with bacteria at 37°C for 18-24 hours. The compound enhances the effectiveness of oxacillin by significantly lowering its MIC.
|
| Cell Assay |
For in vitro cell-based experiments, 2,7-dibromocarbazole is not typically used directly in cell culture for therapeutic applications. It is a chemical reagent used for the synthesis of compounds that may be tested in cell-based assays. The compound itself is primarily used in materials science for the fabrication of OLEDs and OPVs.
|
| Animal Protocol |
In vivo animal studies for 2,7-dibromocarbazole are not applicable, as the compound is primarily used as a building block for materials science and chemical synthesis. No animal studies have been conducted for this compound as a therapeutic agent, and it is not intended for diagnostic or therapeutic use in animals or humans.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 2,7-dibromocarbazole are not available, as the compound is not a drug and is not administered to living organisms. The compound has a molecular weight of 325.00 g/mol, a melting point of 227-231°C, a boiling point of 459°C, and a density of 1.93 g/cm³. It should be stored in a cool, dry place.
|
| Toxicity/Toxicokinetics |
2,7-Dibromocarbazole is a research chemical and should be handled with appropriate laboratory safety precautions. As a brominated compound, it may cause skin and eye irritation. The compound should be stored in a cool, dry place. Specific LD₅₀ values, acute toxicity classifications, and chronic toxicity data are not available in the public literature. Standard safety practices include the use of personal protective equipment.
|
| Additional Infomation |
2,7-Dibromocarbazole belongs to the biphenyl class of compounds and also to the bromobenzene class of compounds.
2,7-Dibromocarbazole (CAS 136630-39-2) is primarily a research-grade chemical intermediate, not an FDA-approved pharmaceutical drug. Its primary applications are as a building block for the synthesis of carbazole-based small molecules and polymers for organic electronics, including OLEDs, OPVs, and OFETs. The compound exhibits antibacterial activity against MRSA strains. No clinical trials or approved indications exist for this compound. |
| Molecular Formula |
C12H7BR2N
|
|---|---|
| Molecular Weight |
325.00
|
| Exact Mass |
322.894
|
| CAS # |
136630-39-2
|
| PubChem CID |
11151503
|
| Appearance |
White to off-white solid powder
|
| Density |
1.9±0.1 g/cm3
|
| Boiling Point |
459.0±25.0 °C at 760 mmHg
|
| Melting Point |
232 °C
|
| Flash Point |
231.4±23.2 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.797
|
| LogP |
5.26
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
0
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
15
|
| Complexity |
222
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
BrC1C([H])=C([H])C2=C(C=1[H])N([H])C1C([H])=C(C([H])=C([H])C2=1)Br
|
| InChi Key |
QPTWWBLGJZWRAV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H7Br2N/c13-7-1-3-9-10-4-2-8(14)6-12(10)15-11(9)5-7/h1-6,15H
|
| Chemical Name |
2,7-dibromo-9H-carbazole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (307.69 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0769 mL | 15.3846 mL | 30.7692 mL | |
| 5 mM | 0.6154 mL | 3.0769 mL | 6.1538 mL | |
| 10 mM | 0.3077 mL | 1.5385 mL | 3.0769 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
